February 2010
Worldwide Biotech;Feb2010, Vol. 22 Issue 2, p4
Trade Publication
This article focuses on the Exclusive Test Distribution and Services Agreement executed by Genetic Technologies Limited with Response Genetics Inc. As part of the agreement, Genetic Technologies will exclusively distribute Response Genetics' test panels and proprietary polymerase chain reaction-based molecular diagnostic tests for cancer in Asian markets. Particular focus is given to the prevalence of cancer-related deaths in Australia from 2002-04. Response Genetics President Kathleen Danenberg notes the advantage of their ResponseDX� tests.


Related Articles

  • Response Genetics, Inc. Reports 1st qtr Financial Results and Operational Update.  // Biomedical Market Newsletter;5/16/2011, p228 

    The article offers information on the income and expenditure for the first quarter (Q1) of 2011 ending in March 31, 2011 as well as business update of Los Angeles, California-based Response Genetics Inc., a company specializing on the development and marketing of molecular diagnostics tests for...

  • Deep ion sequencing of amplicon adapter ligated libraries: a novel tool in molecular diagnostics of formalin fixed and paraffin embedded tissues. Becker, Kerstin; Vollbrecht, Claudia; Koitzsch, Ulrike; Koenig, Katharina; Fassunke, Jana; Huss, Sebastian; Nuernberg, Peter; Heukamp, Lukas C.; Buettner, Reinhard; Odenthal, Margarete; Altmueller, Janine; Merkelbach-Bruse, Sabine // Journal of Clinical Pathology;Sep2013, Vol. 66 Issue 9, p803 

    Due to the advanced progress in personalised therapy concepts for non-small cell lung cancer (NSCLC), we applied the ion semiconductor sequencing (ISS) approach to molecular diagnosis of NSCLC, analysing a set of therapy relevant gene loci. DNA from macrodissected tumour samples of formalin...

  • HDC entering gene-based diag with new prostate cancer test. Ford, Omar // Diagnostics & Imaging Week;8/14/2008, Vol. 11 Issue 33, p1 

    This article reveals that Health Discovery Corporation (HDC) has successfully completed a Phase III double-blind trial of a new gene-based test for prostate cancer. Results showed that the test can detect the presence of Grade 3 or higher prostate cancer cells. The company claims 322 prostate...

  • What can breast cancer molecular sub-classification add to conventional diagnostic tools? André, F; Domont, J; Delaloge, S // Annals of Oncology;Sep2007 Supplement 9, Vol. 18, pix33 

    The article discusses the relevance of breast cancer molecular sub-classification to conventional diagnostic tools. It explores the characterization of molecular subclasses using conventional diagnostic tools. A comparison between the clinical performance of molecular subclasses and conventional...

  • Response Genetics, Inc. to Release 4th Qtr and Full-Year 2010 Financial Results and Operational Update on March 29 2011.  // Biomedical Market Newsletter;4/30/2011, p296 

    The article reports on the plan of Response Genetics Inc. to release 4th quarter and full-year 2010 financial results in a press release on March 29, 2011. It discusses the focus of the company on sale and development of molecular diagnostic tests for cancer. It mentions that the technologies of...

  • Agreements/contracts.  // Medical Device Daily;1/7/2010, Vol. 14 Issue 4, p4 

    The article discusses the exclusive distribution and services contract signed by Response Genetics and Genetic Technologies. Under the agreement, Response Genetics' ResponseDX genetic test panels will be exclusively distributed by Genetic Technologies in several countries, including Australia,...

  • NMP technology helps manage bladder cancer. Guttman, Cheryl // Urology Times;Sep96, Vol. 24 Issue 9, p33 

    Features the Matritech NMP22 Test Kit. Help in management of patients with transitional cell carcinoma who have undergone surgery for bladder cancer; Determination of nuclear matrix protein (NMP); Testing; Contact information.

  • Financings roundup.  // Medical Device Daily;3/3/2009, Vol. 13 Issue 40, p2 

    The article reports on the purchase agreement entered into by Response Genetics with certain affiliated funds of Special Situations Funds in order to raise $2 million from the private placement of two million newly issued shares of its common stock. Response is a firm that develops and sells...

  • Response Genetics Regains NASDAQ Compliance.  // Biomedical Market Newsletter;2/21/2012, Vol. 21, p1 

    The article informs that Response Genetics Inc. has regained compliance with the NASDAQ Capital Market and its minimum market value of listed securities requirement. The Company was notified by NASDAQ on February 16, 2012 that the delisting matter is now closed. Response Genetics focuses on the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics